| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	
																	
																	HC Wainwright & Co. analyst Andrew S. Fein maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and lowers the p...
																	Needham analyst Ami Fadia maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and lowers the price target from $18 ...
																	
																	
																	Day One Biopharmaceutical (NASDAQ:DAWN) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimat...
																	
																	Needham analyst Ami Fadia maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and lowers the price target from $30 ...